Hope so Jim! DRGG off a bit here, added WEDX 1.70 +.21 on it's 74.8% interest in NCST which is up big today at 5.50 +1.45! Here is info in Q3 report: Westaim announces 2006 third quarter results
Tuesday November 7, 4:17 pm ET
CALGARY, Nov. 7 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the third quarter ended September 30, 2006, it recorded a net loss of $9.6 million or 10 cents per share, on revenues of $8.2 million. In the same quarter last year, the company recorded a net loss of $5.0 million, or 5 cents per share, on revenues of $12.3 million. The change in revenue and net loss in the third quarter of 2006 compared to 2005 is primarily attributable to $5.9 million in milestone revenue recorded in 2005.
ADVERTISEMENT
At September 30, 2006, Westaim had consolidated $70.7 million in cash and short-term investments.
"Westaim continues to place top priority on executing our business strategy and we are encouraged by the progress made through the first three quarters of 2006," said Barry M. Heck, President and CEO of The Westaim Corporation. "We were pleased with the new potential partner interest in iFire's TDEL technology as well as the continued progress at the pilot facility toward generating the process repeatability data required to secure a manufacturing partner. Westaim believes NUCRYST's nanocrystalline silver technology platform holds tremendous value and we support NUCRYST's continued pursuit of new product opportunities."
NUCRYST's wound care division reported revenues of $8.2 million in the third quarter compared to $12.3 million in the same period last year. NUCRYST's operating loss, reported in Westaim's consolidated results, was $2.6 million compared to net income of $4.9 million last year, a decline primarily attributable to higher clinical study and R&D expenditures and $5.9 million in milestone revenues earned in the third quarter of 2005 under an agreement NUCRYST has with Smith & Nephew plc.
The Westaim Corporation's technology investments include iFire Technology Corp., which has developed a low-cost flat panel display and a 74.8 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX; NCS), which develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. Westaim's common shares are listed on NASDAQ under the symbol WEDX and on The Toronto Stock Exchange under the trading symbol WED.
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
Acticoat(TM) is a trademark of Smith & Nephew plc
This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements involving Westaim's progress in executing its business strategy, potential partner interest in iFire's TDEL technology, iFire's progress toward process repeatability data, the value of NUCRYST's nanocrystalline silver technology, and NUCRYST's pursuit of new product opportunities. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
THE WESTAIM CORPORATION
Financial Highlights
(unaudited)
(thousands of dollars except per share data)
-------------------------------------------------------------------------
Three Months Ended Nine Months Ended
September 30 September 30
--------------------- ----------------------
Consolidated Statements
of Operations 2006 2005 2006 2005
-------------------------------------------------------------------------
Revenue $ 8,203 $ 12,268 $ 22,451 $ 22,953
Loss from continuing
operations (9,552) (5,130) (39,538) (24,991)
Net loss (9,552) (5,042) (39,538) (12,728)
Loss per common share -
basic and diluted
Continuing operations (0.10) (0.06) (0.42) (0.27)
Net loss (0.10) (0.05) (0.42) (0.14)
Weighted average number of
common shares outstanding
(thousands) 93,944 92,851 93,369 92,836
-------------------------------------------------------------------------
Three Months Ended Nine Months Ended
September 30 September 30
--------------------- ----------------------
Segmented Information
- Continuing Operations 2006 2005 2006 2005
-------------------------------------------------------------------------
Revenue
Nucryst Pharmaceuticals $ 8,203 $ 12,268 $ 22,451 $ 22,953
-------------------------------------------------------------------------
Continuing operations $ 8,203 $ 12,268 $ 22,451 $ 22,953
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Operating (loss) income
Nucryst Pharmaceuticals $ (2,638) $ 4,916 $ (9,016) $ 3,677
iFire Technology (8,443) (8,328) (28,731) (23,728)
Other (including
corporate costs) 229 (1,880) (4,817) (6,105)
-------------------------------------------------------------------------
Continuing operations $ (10,852) $ (5,292) $ (42,564) $ (26,156)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Consolidated Balance September December
Sheets 30, 2006 31, 2005
------------------------------------------------
Cash and short-term
investments $ 70,673 $ 119,627
Current assets 89,440 136,169
Other assets 71,759 76,292
Current liabilities 17,746 26,614
Shareholders' equity 123,473 157,640
--------------------------------------------------------------------------------
Source: Westaim Corporation |
